The Aubagne-based facility will use the funds to expand production capacity, and aims to launch 50 new products by the end of 2018.
SSB Finance and Controlling Director Olivier Guitard did not disclose the full range of products planned, but told BioPharma-Reporter that the company will further invest in its portfolio of single-use biomanufacturing technologies.
Guitard said that currently, 75% of vaccines fabricated and used in Europe have been in contact with SSB’s single-use bags at some point during their fabrication.
One of the first products to be launched will be a new, 2,000L single-use bag, to be released next month. At approximately 3m in height and 1m in width, the mechanical-strength bag will include temperature and pH monitoring capabilities, and will serve the Bio Pharma market worldwide.
200 new jobs
Guitard told BioPharma-Reporter La Region Provence-Alpes Cote d’Azur and la Metropole Aix-Marseille Provence have invested in these new technologies to promote the healthcare market in the South of France.
These government bodies are also looking to promote the local job market, said Guitard. SSB has announced the creation of 200 new jobs by the end of 2018.